Introduction
============

Bipolar disorder (BD) is a psychiatric illness characterized by disabling episodes of depression and mania that greatly increase the risk of suicide.^[@bib1]^ The biological origins of BD are poorly characterized, but heritability is estimated to be 0.85, suggesting a genetic etiology.^[@bib2]^ Disturbances in sleep and activity are common in BD, leading to the hypothesis that circadian rhythm disruption is an essential feature of the illness (as reviewed in McCarthy and Welsh^[@bib3]^). The cellular clock comprises ∼20 'clock genes\' that form transcriptional--translational feedback loops to maintain ∼24 h cycles of gene expression and downstream processes.^[@bib4]^ Variants in clock genes have been associated with BD, major depression and seasonal affective disorder.^[@bib3]^ Functional features of the molecular clock are defined by the transcriptional activity of CLOCK/BMAL1 heterodimers that stimulate gene expression through E-box elements in the promoters of *PER1/2/3* and *CRY1/2* genes, with subsequent feedback inhibition by CRY and PER proteins. In the forebrain, NPAS2 may substitute for CLOCK.^[@bib5],\ [@bib6]^ Secondary loops (e.g. RORA/B/C, REV-ERBα), and post-translational modifications by casein kinases 1δ/ɛ (encoded from CSNK1D/E) and glycogen synthase kinase 3β (GSK3β) regulate core loop functions, through alterations in protein stability and nuclear compartmentalization.^[@bib7]^ Accordingly, inhibition of GSK3β increases amplitude and shortens period of gene expression rhythms.^[@bib8],\ [@bib9],\ [@bib10]^

The mood stabilizer lithium (Li) often improves depression and mania, reduces suicide risk and normalizes daily rhythms in BD, but BD is heterogeneous, with Li-responsive and non-responsive sub-types that may differ in important ways. Among its molecular targets, Li inhibits GSK3β,^[@bib11]^ a feature of the drug that may account for the effects on both mood and the clock.^[@bib12]^ Indeed, some studies have identified genetic variants in GSK3β,^[@bib13],\ [@bib14]^ (but see references [@bib15] and [@bib16]), or clock gene substrates of GSK3β (e.g. REV-ERBα) that predict clinical response to Li.^[@bib17],\ [@bib18]^ Li increases the amplitude of *PER2* rhythms in cells and tissue slices,^[@bib10],\ [@bib19],\ [@bib20]^ a feature of the drug that may bolster weak rhythms in some cells. Unlike selective GSK3β inhibitors, Li lengthens the period of behavioral rhythms,^[@bib21],\ [@bib22],\ [@bib23]^ a paradox that could indicate the presence of additional Li targets within the clock network. However, no study has adequately examined the connection between Li and circadian clock function in cells from BD patients. Therefore, it is unknown if Li affects rhythms distinctly in BD. The finding that fibroblasts and neurons have cell autonomous molecular clocks operating through similar mechanisms^[@bib24]^ suggests that this question is amenable to study in skin fibroblasts from BD patients.^[@bib25]^

Our principal hypothesis was that clock gene rhythms and their response to Li would differ in cells from BD patients compared to controls. As secondary hypotheses, we investigated whether clock gene variants and clinical subtypes of BD were associated with differences in rhythms. Supporting our hypotheses, we report that cells from BD patients have longer circadian rhythm periods, and show significant differences in response to Li.

Methods
=======

*Per2::luc* reporter
--------------------

The *Per2::luc* lentiviral reporter gene was provided by Andrew Liu (University of Memphis), and has been described previously.^[@bib24]^ All experiments used ∼1 × 10^7^ infectious units/plate. Transduction efficiency was estimated to be ∼80--100%.

Drugs
-----

Li chloride was purchased from Sigma. Stock Li solutions were made from sterile water at a concentration of 1 [M]{.smallcaps} and used to make the appropriate drug-containing cell culture media.

Human subjects and cell lines
-----------------------------

Subjects 18--65 years old were recruited from McLean Hospital (cases) and the surrounding community (healthy controls). BD cases were typically identified while inpatients on a psychiatric unit. All subjects provided informed consent and were paid to participate. Subjects were evaluated with a structured interview (SCID-Mini for DSM-IV) to establish diagnosis. All cases had a primary diagnosis of BD type I. Clinical features including age of onset, psychiatric family history, dysphoric/euphoric mania, past suicide attempts (PSA), alcohol/substance use history were extracted from the diagnostic interview. Most of the BD patients were on multiple psychotropic medications (mean 3.3). Medications at the time of biopsy were recorded ([Supplementary Table S1](#sup1){ref-type="supplementary-material"}), but details regarding past medication trials and treatment response were not available. Subjects were excluded if they were medically ill or had a history of adverse events with skin biopsies. Age-matched controls were excluded for any psychiatric diagnosis, or use of psychotropic medication.

Fibroblast cell lines were established from skin biopsies from the buttock.^[@bib26]^ De-identified cell lines were subsequently sent to a collaborating laboratory for culture and analysis. At the time of experiments, cell lines had been passaged 3--10 times. Case-control matching was maintained during cell culture procedures and experiments.

Cell culture and luminometry
----------------------------

For reporter gene assays, cells were grown to confluence in 100-mm plates in standard culture media \[DMEM with 10% fetal bovine serum (FBS), glutamine and antibiotics (penicillin, streptomycin and amphotericin)\]. After 2 days, cells were dissociated with trypsin, and ∼10% of each culture was transferred into one of six identical 35-mm plates (duplicates of vehicle, Li 1 m[M]{.smallcaps} and Li 10 m[M]{.smallcaps}) and stabilized for 48 h. Afterwards, transduction with the *Per2::luc* construct proceeded over 48 h as cells were grown to confluence (∼1.2 × 10^6^ cells/plate). Immediately before luminometer assay, growth medium was replaced with HEPES-buffered, serum-free recording media containing 1 m[M]{.smallcaps} luciferin (Biosyth International, Staad, Switzerland) as described previously.^[@bib27]^ This procedure was sufficient to synchronize *Per2::luc* rhythms without serum shock. For experiments with Li (1 or 10 m[M]{.smallcaps}), drug was continuously present in the growth medium, starting 48 h before recording, and throughout the recording period for a total exposure of ∼7 days.

Rhythm measurements were conducted in 35 mm culture plates as previously described^[@bib28]^ using a 32-well luminometer (Actimetrics, Wilmette, IL, USA). Photoemissions were measured from duplicate plates of each sample for 70 s, every 10 min for ∼5 days. Temperature was maintained at 35 °C.

Gene expression
---------------

For analyses of *BMAL1*, *CLOCK* and *NPAS2* expression, duplicate cultures (*N*=7 control, 10 BD) were grown in six-well plates. Thirty-six hours prior to collection, the medium was changed to 1 m[M]{.smallcaps} Li or vehicle containing DMEM to synchronize rhythms. Medium was then aspirated, and the plates were frozen at −80 °C. RNA was prepared using a Qiagen (Hilden, Germany) RNeasy kit, following the instructions provided by the manufacturer. Using a high-capacity reverse transcriptase kit, cDNA (∼750 ng) was synthesized following the manufacturer\'s protocol. Taqman RT-PCR was conducted using a Bio-Rad CFX384 thermocycler with primers (Applied Biosystems, Foster City, CA, USA) targeting BMAL1 (*ARNTL*), *CLOCK*, *NPAS2* and *GAPDH*, a non-rhythmic control gene suitable for circadian rhythm studies.^[@bib29]^ Gene expression was measured against *GAPDH* using the comparative Ct method.^[@bib30]^ Data were normalized to the vehicle-treated control condition.

DNA preparation and genotyping
------------------------------

DNA was prepared from cells using a Qiagen DNeasy Kit following the manufacturer\'s protocol. One single-nucleotide polymorphism (SNP) from each of 14 clock genes was selected for study, based on minor allele frequencies that permit examination in small samples, and where possible, an association with a relevant mood phenotype ([Table 1](#tbl1){ref-type="table"}). Most genotyping was done using pre-designed Taqman assays (Applied Biosystems). For the *PER2* SNP rs56013859, a custom Taqman assay was purchased using published sequence.^[@bib35]^ PCR reactions were conducted as described above.

Data analysis
-------------

For each cell line, luminometry data were averaged and fitted to a damped sine curve by the least squares method using commercial software (Lumicycle Analysis, Actimetrics). To limit variability, the first 0.6 days were excluded from analysis. Data were filtered using moving average background subtraction. Rhythm parameters were defined as period, amplitude and goodness of fit as an index of rhythm robustness. Phase was correlated to period and for this reason, was not considered separately. For two-way analyses of rhythms, parameters were analyzed separately using an unpaired, two-tailed *t*-test or Mann--Whitney *U*-test. For analyses of Li-induced changes in rhythms, a two-way analysis of variance with repeated measures was conducted for each parameter. Correlations were established using Pearson\'s test. All analyses were conducted using GraphPad Prism version 5.0 (San Diego, CA, USA). *P*-values \<0.05 were employed as the threshold for significance in primary analyses. The Benjamini--Hochberg correction for multiple comparisons employing a false discovery rate of 0.05^[@bib36]^ was applied to secondary analyses using publicly available software (Q-Value). After this correction, *P*-values \<0.001 remained significant. *P*-values \<0.05 that fell short of significance after false discovery rate correction were reported as nominally significant.

Results
=======

Baseline rhythm parameters
--------------------------

Robust oscillations in *Per2::luc* gene expression were present in all cell lines (goodness of fit \>80%). Consistent with previous reports of peripheral cell cultures, rhythms were detectable in all cultures for \>5 days before eventual rhythm damping, likely reflecting desynchronization.^[@bib37]^ In our primary analysis examining rhythm parameters among BD cases and controls, rhythm amplitude was similar between groups. However, period was longer by ∼25 min in BD cells compared with controls (controls 25.1±0.2 h vs BD 25.5±0.2 h, mean±s.e.m., U=104.5, *P*\<0.03, [Supplementary Table S2](#sup1){ref-type="supplementary-material"}).

Li treatment and rhythms
------------------------

Li is chronically dosed in BD patients to serum concentrations of 0.5--1.0 m[M]{.smallcaps}, whereas past *in vitro* studies have used Li concentrations \>10 m[M]{.smallcaps}.^[@bib7],\ [@bib10]^ In order to investigate both conditions, we used Li concentrations of 1 m[M]{.smallcaps} and 10 m[M]{.smallcaps}. While there was heterogeneity among individual samples, Li 1 m[M]{.smallcaps} on average did not lengthen period in either control or BD cells. Li 1 m[M]{.smallcaps} increased amplitude by ∼36% in control cells (31.7 vehicle vs 43.2 Li, *P*\<0.01, [Figure 1a](#fig1){ref-type="fig"}), but failed to significantly increase amplitude in BD cells (31.7 vehicle vs 35.5 Li, *P*=0.38, [Supplementary Table S3](#sup1){ref-type="supplementary-material"}, [Figure 1b](#fig1){ref-type="fig"}).

In agreement with previous studies, Li 10 m[M]{.smallcaps} caused period lengthening in control and BD cells ([Supplementary Table S4](#sup1){ref-type="supplementary-material"}, [Figures 1c and d](#fig1){ref-type="fig"}), with a trend toward greater period lengthening in controls compared to BD (0.9 h control vs 0.4 h BD, *P*=0.09). In contrast to the lower concentration, Li 10 m[M]{.smallcaps} increased the mean *Per2::luc* signal, but significantly suppressed amplitude (*P*\<0.0001) after subtracting the non-rhythmic component. This amplitude reduction was similar between groups, with decreases of 27% and 37% for controls and BD respectively. There was no significant drug × genotype interaction.

Analysis of CLOCK, BMAL1 and NPAS2 expression
---------------------------------------------

Rhythmic expression of PER2 is driven by heterodimeric CLOCK:BMAL1 or CLOCK:NPAS2 complexes binding to E-box promoter elements. Like *PER2*, *BMAL1* and *NPAS2* expression is rhythmic, but with a different phase, peaking ∼12 h earlier than *PER2*. While *CLOCK* has an important role in mediating *PER2* rhythms, its expression can be rhythmic or constitutive depending on the tissue, and rhythmic expression is not essential for *CLOCK*\'s function.^[@bib34]^ In an initial examination of the molecular mechanisms by which amplitude was increased after treatment with Li 1 m[M]{.smallcaps} in control but not BD cells, we measured expression of *BMAL1*, *CLOCK* and *NPAS2* in fibroblasts 36 h after a synchronizing medium change, with or without Li 1 m[M]{.smallcaps} added to the medium. Based on the results of *Per2::luc* experiments, this is a time when peak expression of all three genes is expected. However, at this time point there were no differences in *BMAL1*, *CLOCK* or *NPAS2* expression between BD cases and controls either at baseline or after Li treatment ([Supplementary Table S5](#sup1){ref-type="supplementary-material"}). Because the heterodimer is the functional unit for the relevant gene products, and CLOCK and NPAS2 compete for BMAL1 binding, the ratios of *CLOCK/BMAL1*, *CLOCK/NPAS2* and *NPAS2/BMAL1* were each calculated ([Supplementary Table S6](#sup1){ref-type="supplementary-material"}). Li significantly decreased the ratio of *CLOCK/NPAS2* (*P*=0.02), and increased the ratio of *NPAS2/BMAL1* (*P*=0.01), but these effects were similar among BD cases and controls. Therefore, although Li may increase the relative contribution of *NPAS2* to *PER2* regulation, we found no changes in peak *BMAL1*, *CLOCK*, or *NPAS2* expression that might explain why *Per2::luc* rhythm amplitude was increased by Li 1 m[M]{.smallcaps} in control, but not BD cells.

Genetic variation in the clock and Li
-------------------------------------

As a secondary analysis, we examined clock gene variants as predictors of Li-induced rhythm changes. Minor allele frequency and overall burden of variant clock gene alleles did not significantly differ between BD cases and controls ([Table 1](#tbl1){ref-type="table"}). However, when period and amplitude were examined as quantitative traits under baseline and Li-treated conditions, two of these variants were nominally associated with period lengthening, independent of BD diagnosis *(RORA* rs12912233, and *PER3* rs228729, [Figures 2a and b](#fig2){ref-type="fig"}). Homozygotes for the common T allele in *RORA* showed period lengthening with Li 1 m[M]{.smallcaps}, but heterozygous or homozygous carriers of the variant C allele did not (*P*\<0.05). Carriers of the *PER3* variant C allele were more sensitive to the effect of Li 10 m[M]{.smallcaps} in an allelic copy number-dependent manner (*P*\<0.001). Interestingly, the *RORA* SNP has previously been associated with depression traits by genome-wide association study,^[@bib31]^ and the *PER3* variant has been associated with BD.^[@bib38]^

GSK3β SNP rs334558 (−50T/C) has previously been associated with clinical response to Li in both BD and major depression.^[@bib13],\ [@bib14]^ With respect to rhythms, there were nominally significant interactions (*P*\<0.05) between GSK3β genotype and diagnosis: cells from BD subjects carrying the variant C allele showed increased amplitude in the presence of Li 1 m[M]{.smallcaps}, similar to the controls of either genotype, but BD cells homozygous for the common T allele did not ([Figure 2c](#fig2){ref-type="fig"}). GSK3β genotype also predicted period lengthening by Li 10 m[M]{.smallcaps}, but again only in BD cell lines, with a main effect of diagnosis (*P*\<0.05), and a significant diagnosis × genotype interaction (*P*\<0.001). Control cells demonstrated period lengthening regardless of GSK3β genotype, BD cells with the homozygous T/T genotype showed no change in period, and cells with C/C or T/C GSK3β genotypes showed period lengthening, similar to controls ([Figure 2d](#fig2){ref-type="fig"}). Period and amplitude were not correlated in the study population as a whole, suggesting that this pattern of genetic association reflects non-redundant contributions of GSK3β to amplitude and period effects.

Clinical subtype associations
-----------------------------

Clinical features have been used to predict Li response and suicide risk in BD.^[@bib39]^ We conducted secondary analyses of the rhythm data to assess differences among BD sub-phenotypes. Neither PSA, comorbid alcohol use disorder/substance use disorders, nor family history of BD in first degree relatives were associated with any difference in baseline rhythm parameters. Subjects with only euphoric manias (compared with sometimes/always dysphoric) had slightly less rhythm robustness (goodness of fit: 85% dysphoric, 78% euphoric, *P*\<0.05), but did not differ in period or amplitude ([Supplementary Table S7](#sup1){ref-type="supplementary-material"}). Female sex was nominally associated with exclusively euphoric mania, and negatively associated with rhythm robustness (goodness of fit: female 75.7% vs male 84.8%, *P*\<0.01). Age, age of BD onset and illness duration did not correlate with any rhythm parameter. Among controls, age and sex did not correlate with any rhythm parameter.

Using the phenotypic and demographic variables above, we also examined the clock gene response to Li in BD cells by clinical features. Unlike controls and BD subjects considered collectively, BD subjects with a history of PSA demonstrated nominally significant period lengthening after treatment with Li 1 m[M]{.smallcaps} ([Figure 3a](#fig3){ref-type="fig"}). Under the same conditions, there was a trend towards amplitude increases in the PSA positive group, but it was not statistically significant ([Figure 3b](#fig3){ref-type="fig"}). However, when suicide history was assessed as a quantitative measure (number of PSAs), there were nominally significant correlations (*P*\<0.05) between PSA and period lengthening by Li 1 m[M]{.smallcaps} (*r*=0.47, *P*\<0.05, [Figure 3c](#fig3){ref-type="fig"}). The correlation between PSA and amplitude increase by Li 1 m[M]{.smallcaps} was also significant (*r*=0.50, *P*\<0.05, [Figure 3d](#fig3){ref-type="fig"}), but was strongly affected by a single data point with 4 PSAs, and was no longer significant when this subject was excluded. Comorbid alcohol use disorder/substance use disorder, family history or demographic variables were not associated with any changes in rhythm parameters after treatment with Li 1 m[M]{.smallcaps}. With Li 10 m[M]{.smallcaps}, amplitude was nominally higher in the dysphoric mania BD subgroup compared with those with euphoric mania only (23.4 vs 15.2 relative units, *P*\<0.05). There were no further BD subgroup differences in response to Li 10 m[M]{.smallcaps} when considering alcohol use disorder/substance use disorder, PSA, family history or age/sex.

Li augments rhythm resynchronization
------------------------------------

The effect of Li on amplitude suggests that the drug may bolster weak or failing rhythms in vulnerable cell populations, by improving rhythm amplitude. We tested this hypothesis in fibroblasts from control and BD subjects. Rhythms in untreated cells were allowed to damp over 5 days, and were then subjected to medium change, a stimulus commonly used to resynchronize rhythms in cell cultures. The medium change partially restored rhythms in the absence of Li, but the resulting rhythm was typically weak with low amplitude and period exceeding the duration typically considered circadian (\>30 h), consistent with poor synchronization among cells. When Li 10 m[M]{.smallcaps} was included in the medium, rhythms were more robustly restored, more closely resembling the initial signal, with higher amplitude and period closer to 24 h ([Figures 4a--c](#fig4){ref-type="fig"}). Statistical analysis revealed significant medium change × drug interactions for both amplitude (*P*\<0.04, [Figure 4a](#fig4){ref-type="fig"}) and period (*P*\<0.0001, [Figure 4b](#fig4){ref-type="fig"}), favoring rhythm restoration in Li-treated cells. The augmentation of rhythms by Li was similar in BD cases and controls (*N*=5 Li treated of each), suggesting that despite the relative insensitivity of BD cells to Li compared with controls when rhythms are robust, BD cells remain Li sensitive when synchronization and/or amplitudes are weak and that therapeutic benefits of Li related to clock function in BD may be preferentially engaged when rhythms are attenuated.

Discussion
==========

Overview
--------

Evidence from a range of sources supports the notion that the biological clock is perturbed in BD, and that Li restores rhythms.^[@bib3]^ However, definitive demonstration of cellular clock abnormalities in BD has proven elusive. We have shown in fibroblasts from BD patients that the cellular clock is functional, but generally runs slow, with a longer period, and is less sensitive to Li modulation. Among BD cases, variability in the rhythm response to Li is associated with clinical and genetic factors already known to be associated with clinical outcomes among BD patients. Although we do not know the clinical Li response history of our BD subjects, and cannot determine causality from these observations, the association of rhythm parameters with GSK3β, a known genetic predictor of response, suggests that some of Li\'s therapeutic mechanisms may overlap with elements of the cellular clock, and could form the basis of a future biomarker for BD and/or Li response.

Effect of Li on rhythms
-----------------------

The period lengthening effect of Li on circadian rhythms is well established,^[@bib21],\ [@bib22],\ [@bib23]^ and recent studies using bioluminescent cellular reporters have shown that Li increases amplitude.^[@bib10],\ [@bib19],\ [@bib20]^ Our results generally agree with past reports, and extend these findings to include clinical samples from BD patients. We have also shown that the relative contribution of CLOCK and NPAS2 in governing rhythms may be affected by Li, but occurs at concentrations below those required to alter period, and is unrelated to the differential modulation of amplitude observed in BD cases. Therefore, this level of transcriptional regulation by Li may be unimportant to PER2 regulation, but could conceivably influence the expression of other rhythmic genes (that is PER1/3, CRY1/2). However, our work also underscores the heterogeneity among individual responses, and differs in some respects from past work. Specifically, our results show that at higher concentrations of Li, the effect on amplitude is complex with greater overall expression of Per2::luc, but suppression of the rhythmic component after background subtraction. Our observations in human and mouse cells indicate these differences are explained to some extent by chronic vs acute Li dosing, and species. Of particular importance to BD, there may be important differences between neurons and fibroblasts, with indications that fibroblasts require higher concentrations of Li to influence rhythms.^[@bib10]^

Rhythm differences between BD cases and controls
------------------------------------------------

We found longer circadian periods of *Per2::luc* rhythms in BD compared with controls. Long free running periods cause a delay in activity onset. Hence, this finding could point to a genetic basis for the nocturnal preference reported in BD patients who may experience the drive for peak activity later in the day.^[@bib40]^ A previous study of BD fibroblasts using PCR-based measurements did not find differences in circadian period,^[@bib41]^ but the *Per2::luc* method we used measures rhythms at a higher sampling density, and therefore the discordant results may be due to the increased sensitivity of our technique compared with older methods. The same study did report reduced amplitudes of BMAL1, Rev-Erbα and DBP rhythms.^[@bib41]^ Similarly, amplitude abnormalities in behavior have been reported in actigraphy studies of euthymic BD patients.^[@bib42]^ We did not find evidence of lower *Per2::luc* amplitude at baseline in BD, and did not measure amplitude of BMAL1, Rev-Erbα or DBP rhythms. However, we report that Li increases *Per2::luc* amplitude at therapeutic concentrations, consistent with the idea that Li could reverse putative rhythm defects reported by others.

In general, cells from BD patients were less responsive to Li\'s modulation of amplitude (and perhaps period) than were controls. Taken together, these findings could indicate that the clock in BD is not particularly impaired at baseline, but may be less flexible, and not as responsive to conditions that would normally shift the clock. This finding might be relevant to observations that disruptions to light--dark or sleep schedules can trigger mood episodes in individuals susceptible to BD.^[@bib43]^ Alternatively, past exposure to Li and/or other psychotropic medications may have had lasting effects on the Li sensitivity of cellular rhythms. As BD cell line donors were more likely to be exposed to medication than controls, this could, in principle, explain the differences between groups, but requires the presence of a long-lasting mechanism to explain the result after multiple passages of cell culture. To date, no such mechanism has been described. Regardless of the mechanism, when rhythms were attenuated by damping, both BD and control cells showed a similar degree of improvement in rhythms after Li. Interestingly, valproic acid has been reported to increase rhythm amplitude.^[@bib19]^ Although this drug has not been examined in BD cell lines, the similar amplitude-enhancing effects of Li and valproic acid suggest the possibility of a common circadian mechanism among mood stabilizers. Further, despite the insensitivity of the BD clock to Li, these results suggest that low amplitude clocks may become desynchronized, and benefit from amplitude-enhancing treatments to facilitate resynchronization. This may be relevant to cell populations in the brain that govern mood, some of which express clock genes and/or have circadian oscillators (as reviewed in McCarthy and Welsh^[@bib3]^). In contrast, the effect of Li on period may worsen the already longer period in BD, further delaying activity onset, and the period effect is prominent only at supratherapeutic concentrations. For these reasons, we hypothesize that any therapeutic effect of Li on the clock is primarily due to modulation of amplitude, and not period.

Li-responsive BD and circadian rhythms
--------------------------------------

BD is commonly divided into Li-responsive and non-responsive types.^[@bib44]^ We do not have data on the clinical Li-responsiveness of the BD patients from which our cells were derived, but we did examine clinical and genetic features previously shown to be associated with Li-responsiveness. Classical Li responders have few comorbid psychiatric diagnoses, a positive family history of BD, and a preponderance of euphoric manias.^[@bib39]^ We did not find clear differences in rhythms across these clinical dimensions. However, genetic factors, including some that predict clinical Li response, were associated with Li-induced changes in rhythms. We have shown previously that expression of clock genes, and genes strongly regulated by the clock are preferentially modulated by Li.^[@bib45]^ Moreover, clinical Li response has been previously associated with genetic variants in the circadian clock, including the −50T/C SNP in GSK3β, and Rev-Erbα.^[@bib17],\ [@bib18]^ The −50T/C SNP is thought to affect the GSK3β promoter, with the C allele associated with lower gene expression, perhaps phenocopying the effects of Li inhibition of the enzyme.^[@bib18]^ In the present study, GSK3β genotype was associated with amplitude increase in response to Li 1 m[M]{.smallcaps}, and also with period lengthening at Li 10 m[M]{.smallcaps}, but only in BD cell lines. For both parameters, there was a genotype × diagnosis interaction, suggesting that the function of GSK3β in rhythm regulation differs in control and BD cells. This finding suggests that GSK3β may have a distinctive role in BD, consistent with numerous reports implicating it as a pathogenic factor in the illness.^[@bib46],\ [@bib47],\ [@bib48],\ [@bib49],\ [@bib50]^

Functional implications for Li and genetic variation in the clock
-----------------------------------------------------------------

In addition to the BD-specific differences associated with GSK3β, we identified two variants in PER3 and RORA that were associated with period length after Li in both BD cases and controls, suggesting these may reflect variation in the clock that is not necessarily pathogenic for BD, but may influence the course of Li treatment. The RORA variant is intronic, with presumptive regulatory function. Of interest, other variants in RORA have been independently associated with anti-depressant response,^[@bib51]^ post-traumatic stress disorder^[@bib52]^ and BD^[@bib53]^ suggesting the RORA gene may be vulnerable in multiple psychiatric conditions. The PER3 variant is in almost perfect linkage disequilibrium with the variable number tandem repeat (VNTR) polymorphism. The VNTR is predicted to alter protein coding sequence of PER3, changing the number of sites available for casein kinase 1ɛ phosphorylation.^[@bib54]^ In addition to BD,^[@bib55]^ the VNTR has been associated with diurnal preference, and sleep abnormalities.^[@bib56]^ Therefore, while the effect of this PER3 variant on period in our experiment is similar between BD cases and controls, it too may have effects on illness progression or treatment, especially in the context of therapeutic Li use.

Suicide and circadian rhythms
-----------------------------

Li has been identified as an anti-suicide drug, reducing risk in BD by fivefold.^[@bib57]^ There is evidence that suicidal behavior is genetically transmitted^[@bib58],\ [@bib59]^ and segregates independently of BD.^[@bib60]^ Diurnal variation in suicide has been suggested, with reports of both nighttime^[@bib61]^ and morning peaks in incidence.^[@bib62]^ More consistently, suicides have been shown to have a seasonal pattern with peaks in spring and autumn.^[@bib63]^ A recent study found *PER1* among several downregulated genes in the prefrontal cortex of suicide victims.^[@bib64]^ In this context, it is interesting that our BD subjects with a suicide history were especially sensitive to Li\'s effects, suggesting that the clock genes may be among those underlying suicide, the most severe pathological feature of BD.

Study limitations
-----------------

Peripheral clocks recapitulate central features of cellular clocks in the brain, but tissue specific factors may be important. Furthermore, our study was small, and underpowered to examine clinical and genetic sub-phenotypes in detail. Due to the number of secondary analyses conducted; there is an increased risk of false-positive associations, and replication will be required. Future efforts will be directed toward testing our novel hypotheses in the context of large, well-powered studies that are amenable to detailed analyses.
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![Fibroblasts from BD patients have an attenuated response to Li. Vehicle, Li 1 m[M]{.smallcaps} or Li 10 m[M]{.smallcaps} was included in the growth medium for 48 h prior to, and continuously during 5 days of recording. Rhythmic *Per2::luc* expression was measured as counts per second (cps) with baseline subtraction. (**a**) Amplitude increased in cells from control (*N*=19, *P*\<0.01), but not BD (*N*=19, *P*=0.32) subjects after Li 1 m[M]{.smallcaps} (error bars indicate 95% confidence intervals). (**b**) There was a non-significant trend toward greater period lengthening in controls compared with BD cells after Li 10 m[M]{.smallcaps} (error bars indicate 95% confidence intervals). Representative vehicle-treated (black) and Li-treated (red) rhythm traces are shown for representative control and BD cell lines at 1 m[M]{.smallcaps} (**c**, **d**) and 10 m[M]{.smallcaps} (**e**, **f**).](tp201390f1){#fig1}

![Rhythm modulation by Li is associated with clock gene variants. (**a**) Period lengthening after Li 1 m[M]{.smallcaps} for *RORA* rs12912233 homozygous common (T/T), heterozygous (C/T) and homozygous variant (C/C) genotypes \[*N*=5/11/3 (controls), *N*=7/9/3 (BD), *P*\<0.05\]. (**b**) Period lengthening after Li 10 m[M]{.smallcaps} for *PER3* rs228729 homozygous common (T/T), heterozygous (T/C) and homozygous variant (C/C) genotypes \[*N*=6/12/1 (controls), *N*=11/6/2 (BD), *P*\<0.001\]. In both cases (**a**,**b**), genotype effects were significant regardless of diagnosis so BD cases and controls have been combined. (**c**) Amplitude increase after Li 1 m[M]{.smallcaps} among GSK3β −50T/C homozygous common (T/T) and rare variant carriers (T/C and C/C). Two-way ANOVA revealed a significant genotype × diagnosis interaction (*P*\<0.05), but no significant difference between genotypes or diagnoses alone. (**d**) Period lengthening after Li 10 m[M]{.smallcaps}. Two-way ANOVA revealed effect of BD (*P*\<0.05), and significant genotype × diagnosis interaction (*P*\<0.001). For homozygous common/heterozygous/homozygous variant genotypes, *N*=8/11/0 (controls) and *N*=9/9/1 (BD), respectively. Error bars indicate s.e.m.](tp201390f2){#fig2}

![Suicide in BD is associated with period lengthening and amplitude increase after Li 1 m[M]{.smallcaps}. When measured categorically, BD patients with a history of suicide were more sensitive to (**a**) period lengthening, but not (**b**) amplitude increase after treatment with Li 1 m[M]{.smallcaps}. *P*-values indicate the results of 1-way ANOVA with *N*=6 PSA positive/13 PSA negative/19 controls. Error bars indicate s.e.m. When measured quantitatively, suicide history is significantly correlated with both (**c**) period lengthening and (**d**) amplitude increase after Li 1 m[M]{.smallcaps}.](tp201390f3){#fig3}

![Li improves rhythm resynchronization. Cellular rhythms (*N*=10 each BD and control) were measured without treatment until damped (dashed line, day 1--5 in panel **a**). In order to restore rhythms, medium change with Li 10 m[M]{.smallcaps} (red) or vehicle (black) was performed on day 5.5 (arrow in panel **a**). Omitting the signal artifact associated with media change, rhythms were then measured another 2 days (solid line in panel **a**). After media change, Li-treated cells had (**b**) significantly higher rhythm amplitudes (*P*\<0.05), and (**c**) lower periods (*P*\<0.001) compared with vehicle-treated cells. Following media change, period in Li-treated cells was in the circadian range (23.1±0.5 h (Ave±s.e.m.)); whereas period in the vehicle-treated cells was not (31.1±1.9 h (Ave±s.e.m.)).](tp201390f4){#fig4}

###### Clock gene SNPs and MAF in BD cases and controls

  *Gene*        *SNP*     *MAF Cont*   *MAF BD*   *Notes*
  ---------- ------------ ------------ ---------- ----------------------------------------
  BMAL1       rs2279287   31.6         13.2       Assoc BD, AKA ARNTL^[@bib38]^
  CLOCK       rs1801260   31.6         26.3       Assoc BD and insomnia^[@bib32]^
  CRY1        rs8192440   26.3         28.9       Assoc Li response^[@bib18]^
  CRY2        rs2037311   2.6          2.6         
  CSNK1E      rs1534891   13.2         10.5        
  GSK3β        rs334558   28.9         28.9       Assoc Li response^[@bib13],\ [@bib14]^
  NPAS2       rs11541353  18.4         23.7       Assoc SAD, AKA S471L^[@bib33]^
  Rev-Erbα    rs2071427   18.4         18.4       Assoc Li response,^[@bib18]^ AKA NR1D1
  PER1        rs3027178   15.8         26.3        
  PER2        rs56013859  15.8         26.3       Assoc SAD,^[@bib33]^ AKA 10870
  PER3         rs228729   36.8         26.3       Assoc BD,^[@bib38]^ tags VNTR
  RORA        rs12912233  44.7         39.5       Assoc depression^[@bib31]^

Abbreviations: Assoc, associated; AKA, also known as; MAF, minor allele frequency; SAD, seasonal affective disorder; SNP, single-nucleotide polymorphism; VNTR, variable number tandem repeat.

In some instances, past illness associations and reference are indicated. Also known as (AKA) indicates alternate name for SNP or gene.
